Twitter | Search | |
This is the legacy version of twitter.com. We will be shutting it down on 15 December 2020. Please switch to a supported browser or device. You can see a list of supported browsers in our Help Center.
Search Refresh
Extracellular Matrix News 3h
🆕 study from , published in ! PAK4 inhibition normalized the tumor vascular and sensitized glioblastoma to chimeric antigen receptor–T cell .
Reply Retweet Like
daniele biasci Nov 26
Excited to be presenting at the Kennedy Institute in Oxford. I will be sharing some new data on FDCSP+ fibroblasts and immunotherapy response.
Reply Retweet Like
Immunosurveillance at @TheCrick & @KingsCollegeLon 19h
Replying to @bsicongress
On Tuesday morning, in a session "Translating Tumor Immunology", we shall explain how lessons learned from COVID-IP are aiding . Our mantra: "Translational product development should be focused; translational science should not".
Reply Retweet Like
Jacinto Convit World Organization Nov 29
Learn more about the development of , our breast vaccine proposed by Dr. Jacinto Convit. We are committed to the development of its clinical phase in the near future and potentially benefit highly vulnerable patients.
Reply Retweet Like
Anniina Färkkilä Nov 25
Extremely grateful to for a three-year grant supporting our work to improve for 💪🏻🎉
Reply Retweet Like
National Centre for Asbestos Related Diseases Nov 25
Congratulations to Dr Rachael Zemek for being awarded Early Career Cancer Researcher of the Year! This award acknowledged her hard work investigating how to improve the efficacy of for cancer patients by the .
Reply Retweet Like
Shiona Ramage Nov 23
Future of immunotherapy in melanoma to focus on overcoming resistance, personalizing regimens via
Reply Retweet Like
The James Nov 25
Researchers are breaking new ground in , showing how a potential vaccine could free up suppressed -fighting cells.
Reply Retweet Like
Prajwal Rajappa M.D., M.S. Nov 25
Feeling thankful for the support of and my team, who continue to show their dedication to science in the face of adversity during this turbulent year. Onward.
Reply Retweet Like
Paolo Tarantino Nov 21
After decades of traditional chemo, a new era for eTNBC is coming Based on the MoA of , I suspect that the best (EFS,OS) is yet to come. However, we’ll need to be patient Congrats for the great presentation on such a relevant subject!
Reply Retweet Like
Zachary Rubin, MD Nov 24
Replying to @DrCorinneHappel
This is a great summary, thanks! I find that most of my patients are sensitized too multiple allergens, so SLIT is not the best option for most of my patients.
Reply Retweet Like
Sam Campos Nov 25
Huge congrats to Mike Kuhns and lab (not on Twitter). They are experts in structure/function of the TCR. It’s been so cool to see this work as it has materialized. It exemplifies the importance of basic science towards translational efforts. Well done Mike! 👏🏼👏🏼👏🏼
Reply Retweet Like
Matt Ocko Nov 22
Another week, another breakthrough company working to transform human health and quality of life from the family. Co-led the first round and doubled down again in - enabling "any tumor to be treated in any patient at any time"
Reply Retweet Like
Ashley Wysong MD, MS Nov 21
Our research team identified patients treated with had an ORR of 42.3%. Interestingly, tumor mutational burden (TMB) was higher among responders vs non-responders (60 vs 9 Mut/Mb).
Reply Retweet Like
Miles Linde Nov 23
Very proud of my big brother and scientific role model, Ian Linde, for the successful defense of his doctoral dissertation! Looking forward to the amazing science he will produce in the future!
Reply Retweet Like
National Centre for Asbestos Related Diseases Nov 25
Director sharing some of the recent work done by our lab, in collaboration with the , to combine with in .
Reply Retweet Like
ASCO Publications Nov 24
Strategic combinations of targeted therapies in oncology to prevent and overcome resistance
Reply Retweet Like
European Hospital Nov 23
The evolving area of immunotherapies in and the role of iRecist treatment assessment protocols were investigated during a virtual session organised by .
Reply Retweet Like
Imugene | Cancer Immunotherapies Nov 23
Our 2020 AGM Presentation is now available for download: Our AGM will start at 9am AEST and log in detail are available from our homepage. ASX: IMU
Reply Retweet Like
National Centre for Asbestos Related Diseases Nov 26
Congratulations again to Dr Joost Lesterhuis and Dr Jonathan Chee for continued Research Fellowship funding from
Reply Retweet Like